Tests INCA036873 in adults with advanced solid tumors and blood cancers
Checks the safety of INCA036873 in adults with advanced cancers or blood cancers.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Key facts
- Where
- Aarhus and Copenhagen, DenmarkSee the 2 sites
- Phase
- Phase 1
Where in Denmark
- Department of Hematology'S Research Unit and Laboratories At Aarhus University HospitalAarhus, DenmarkTaking people
- Rigshospitalet Uni of Hospital of CopenhagenCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07195916EU 2025-523130-11-00
- Record updated
- 9 October 2026
- Original description
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.Read full original descriptionShow less
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Inclusion: Age ≥18 years; ECOG performance status of 0 or 1; Histologically confirmed:; Clear cell renal cell carcinoma (ccRCC); Diffuse large B-cell lymphoma (DLBCL, NOS); High-grade B-cell lymphoma (HGBCL); Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL); Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement); Disease progression, relapse, or refractory to prior therapy:; ccRCC: ≥1 prior line incl. ICI + TKI; DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage; PTCL/CTCL: ≥1 prior systemic therapy; Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL); Tumor tissue available for central testing.
Exclusion: Untreated or progressive CNS disease unless previously treated and stable; Prior CD70-targeting therapy, including CAR T; ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant; Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions); Other active invasive malignancy within 2 years (except certain low-risk cancers); Primary immunodeficiency or active autoimmune disease requiring immunosuppression; Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy; Pregnancy, breastfeeding, or unwillingness to use effective contraception; Other protocol-defined Inclusion/Exclusion Criteria may apply.